Pulmonary function in patients with trophoblastic disease treated with low-dose methotrexate.

The Sheffield Trophoblastic Disease Centre treats about 25 patients with persistent trophoblastic disease each year. A total of 75% of patients are classified as low risk according to the Charing Cross Hospital prognostic scoring system and receive methotrexate (MTX) 50 mg, i.m., on days 1, 3, 5, 7...

Full description

Saved in:
Bibliographic Details
Main Authors: Gillespie, A. M., Lorigan, P. C., Radstone, C. R., Waterhouse, J. C., Coleman, R. E., Hancock, B. W.
Format: Artigo
Language:Inglês
Published: Nature Publishing Group 1997
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2228140/
https://ncbi.nlm.nih.gov/pubmed/9374387
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items